行情

CALA

CALA

Calithera
NASDAQ

实时行情|Nasdaq Last Sale

3.160
+0.010
+0.32%
交易中 12:35 11/12 EST
开盘
3.150
昨收
3.150
最高
3.290
最低
3.150
成交量
8.14万
成交额
--
52周最高
6.90
52周最低
2.450
市值
1.70亿
市盈率(TTM)
-1.4232
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CALA 新闻

  • The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat
  • Benzinga.5小时前
  • Calithera to Present Preclinical Data from IL4I1 and CD73 Programs at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
  • GlobeNewswire.11/05 13:01
  • 3 Small Biotech Stocks Insiders Are Buying
  • Seeking Alpha - Article.11/04 15:56
  • Calithera Biosciences to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019
  • GlobeNewswire.11/04 13:00

更多

所属板块

生物技术和医学研究
+0.14%
制药与医学研究
+0.47%

热门股票

名称
价格
涨跌幅

CALA 简况

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company's lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors.
展开

Webull提供Calithera Biosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。